This discrepancy may be attributable to the greater genetic heterogeneity and aggressive disease biology of Ph+ ALL (36), as well as the lower CD22 antigen density on Ph+ blasts (37), which may impair InO binding and intracellular delivery. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.